Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix (NASDAQ:CMRX) has announced the granting of inducement awards to three new employees on February 12, 2025. The awards consist of non-statutory stock options to purchase up to 270,000 shares of Chimerix's common stock, approved by the Compensation Committee of Chimerix's Board of Directors.
The stock options have an exercise price equal to Chimerix's closing trading price on the grant date and a 10-year term. They will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following three years. While subject to the terms of Chimerix's 2024 Equity Incentive Plan, these grants were made outside of it.
Chimerix is a biopharmaceutical company focused on developing medicines for deadly diseases. Their lead program, dordaviprone (ONC201), is being developed for H3 K27M-mutant glioma, while Phase 1 dose escalation studies of ONC206 are ongoing.
Chimerix (NASDAQ:CMRX) ha annunciato il conferimento di premi di incentivazione a tre nuovi dipendenti il 12 febbraio 2025. I premi consistono in opzioni su azioni non statutarie per l'acquisto di fino a 270.000 azioni ordinarie di Chimerix, approvate dal Comitato per la Retribuzione del Consiglio di Amministrazione di Chimerix.
Le opzioni su azioni hanno un prezzo di esercizio pari al prezzo di chiusura delle azioni di Chimerix alla data di concessione e hanno una durata di 10 anni. Si matureranno nel corso di quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura mensilmente nei successivi tre anni. Sebbene siano soggette ai termini del Piano di Incentivi Azionari 2024 di Chimerix, queste concessioni sono state effettuate al di fuori di esso.
Chimerix è una azienda biofarmaceutica focalizzata nello sviluppo di farmaci per malattie mortali. Il loro programma principale, dordaviprone (ONC201), è in fase di sviluppo per il glioma mutante H3 K27M, mentre sono in corso studi di escalation della dose di fase 1 per ONC206.
Chimerix (NASDAQ:CMRX) ha anunciado la concesión de premios de incentivo a tres nuevos empleados el 12 de febrero de 2025. Los premios consisten en opciones sobre acciones no estatutarias para comprar hasta 270,000 acciones ordinarias de Chimerix, aprobadas por el Comité de Compensación de la Junta Directiva de Chimerix.
Las opciones sobre acciones tienen un precio de ejercicio igual al precio de cierre de Chimerix en la fecha de concesión y un plazo de 10 años. Se adquirirán a lo largo de cuatro años, con un 25% que se adquiere después de un año y el 75% restante que se adquiere mensualmente durante los tres años siguientes. Si bien están sujetas a los términos del Plan de Incentivos de Capital 2024 de Chimerix, estas concesiones se realizaron fuera de él.
Chimerix es una empresa biofarmacéutica centrada en el desarrollo de medicamentos para enfermedades mortales. Su programa principal, dordaviprone (ONC201), se está desarrollando para glioma mutante H3 K27M, mientras que se están llevando a cabo estudios de escalado de dosis de fase 1 para ONC206.
Chimerix (NASDAQ:CMRX)는 2025년 2월 12일 세 명의 신입 직원에게 유인 보상을 부여했다고 발표했습니다. 보상은 Chimerix의 보통주 최대 270,000주를 구매할 수 있는 비법정 주식 옵션으로 구성되며, Chimerix의 이사회 보상 위원회에서 승인되었습니다.
주식 옵션의 행사가격은 부여일의 Chimerix 종가와 같으며, 10년의 유효기간을 가집니다. 이 옵션은 4년에 걸쳐 분할하여 부여되며, 1년 후 25%가 부여되고 나머지 75%는 이후 3년 동안 매달 부여됩니다. Chimerix의 2024년 자본 인센티브 계획의 조건에 따라 진행되지만, 이러한 보상은 그 계획 외부에서 이루어졌습니다.
Chimerix는 치명적인 질병을 위한 의약품 개발에 중점을 둔 생명공학 회사입니다. 그들의 주요 프로그램인 dordaviprone (ONC201)은 H3 K27M 변이 신경교종을 대상으로 개발되고 있으며, ONC206에 대한 1상 용량 증량 연구가 진행 중입니다.
Chimerix (NASDAQ:CMRX) a annoncé le 12 février 2025 l'octroi de primes d'incitation à trois nouveaux employés. Les primes se composent d'options d'achat d'actions non statutaires permettant d'acheter jusqu'à 270 000 actions ordinaires de Chimerix, approuvées par le Comité de Rémunération du Conseil d'Administration de Chimerix.
Les options d'achat d'actions ont un prix d'exercice égal au prix de clôture de Chimerix à la date d'octroi et une durée de 10 ans. Elles seront acquises sur une période de quatre ans, avec 25% acquises après un an et les 75% restants acquises mensuellement au cours des trois années suivantes. Bien qu'elles soient soumises aux termes du Plan d'Incentives en Actions 2024 de Chimerix, ces attributions ont été faites en dehors de celui-ci.
Chimerix est une entreprise biopharmaceutique axée sur le développement de médicaments pour les maladies mortelles. Leur programme phare, dordaviprone (ONC201), est en cours de développement pour le gliome muté H3 K27M, tandis que des études d'escalade de dose de phase 1 pour ONC206 sont en cours.
Chimerix (NASDAQ:CMRX) hat am 12. Februar 2025 die Gewährung von Anreizprämien an drei neue Mitarbeiter angekündigt. Die Prämien bestehen aus nicht gesetzlich vorgeschriebenen Aktienoptionen zum Kauf von bis zu 270.000 Stammaktien von Chimerix, die vom Vergütungsausschuss des Vorstands von Chimerix genehmigt wurden.
Die Aktienoptionen haben einen Ausübungspreis, der dem Schlusskurs von Chimerix am Gewährungstag entspricht, und eine Laufzeit von 10 Jahren. Sie werden über einen Zeitraum von vier Jahren fällig, wobei 25% nach einem Jahr und die restlichen 75% monatlich über die folgenden drei Jahre fällig werden. Obwohl sie den Bedingungen des Aktienoptionsplans 2024 von Chimerix unterliegen, wurden diese Zuwendungen außerhalb dieses Plans gewährt.
Chimerix ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Arzneimitteln gegen tödliche Krankheiten konzentriert. Ihr Hauptprogramm, dordaviprone (ONC201), wird für H3 K27M-mutiertes Gliom entwickelt, während die Phase-1-Dosiserhöhungsstudien für ONC206 im Gange sind.
- None.
- None.
DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on February 12, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 270,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4).
The stock options have an exercise price per share equal to Chimerix’s closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the date of hire and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock options are subject to the terms of Chimerix’s 2024 Equity Incentive Plan but were granted outside of the 2024 Equity Incentive Plan.
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
CONTACTS:
Will O’Connor
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com
FAQ
How many shares of CMRX stock options were granted in the February 2025 inducement awards?
What is the vesting schedule for CMRX's February 2025 inducement stock options?
What is the term length of CMRX's February 2025 inducement stock options?
What is Chimerix's (CMRX) main clinical development program as of February 2025?
What is the exercise price of CMRX's February 2025 inducement stock options?
